PSC: Protect and serve with colitis: Does it help the liver to have severe ulcerative colitis?

Gut

Volumn 60, Issue 9, 2011, Pages 1165-1166

  Rust, Christian ^a   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 21;

COLON RESECTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ENTERITIS; HUMAN; IMMUNITY; IMMUNOPATHOLOGY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; NOTE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS;

CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE;

EID: 80051549463     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2011.240309     Document Type: Note

References (17)

1. Smith MP, Loe RH. Sclerosing cholangitis; review of recent case reports and associated diseases and four new cases. Am J Surg 1965;110:239-46.
2. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6. (Pubitemid 40007225)
3. Broome U, Lofberg R, Lundqvist K, et al. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 1995;38:1301-5.
4. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997;40:451-6. (Pubitemid 27172624)
5. Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008;14:3497-503.
6. Marelli L, Xirouchakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011;60:1224-8.
7. Moncrief KJ, Savu A, Ma MM, et al. The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation - a single-centre experience. Can J Gastroenterol 2010;24:40-6.
8. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011;43:17-19.
9. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010;138:1102-11.
10. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-52.
11. Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARD9. Hepatology 2011;53:1977-85.
12. Stallhofer J, Denk GU, Glas J, et al. Analysis of IL2/IL21 gene variants in cholestatic liver diseases reveals an association with primary sclerosing cholangitis. Digestion 2011;84:29-35.
13. Hsu W, Zhang W, Tsuneyama K, et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha(-/-) mice. Hepatology 2009;49:133-40.
14. Bo X, Broome U, Remberger M, et al. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut 2001;49:131-41. (Pubitemid 32601890)
15. Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 2004;200:1511-17. (Pubitemid 39657298)
16. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006;26:3-21. (Pubitemid 43320723)
17. Berenyi MR, Straus B, Cruz D. In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis. Am J Dig Dis 1974;19:199-205.